231 related articles for article (PubMed ID: 37526084)
1. Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
Li Q; Wang X; Song Q; Yang S; Wu X; Yang D; Marié IJ; Qin H; Zheng M; Nasri U; Kong X; Wang B; Lizhar E; Cassady K; Tompkins J; Levy D; Martin PJ; Zhang X; Zeng D
J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526084
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
[TBL] [Abstract][Full Text] [Related]
3. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
[TBL] [Abstract][Full Text] [Related]
4. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
Front Immunol; 2022; 13():907673. PubMed ID: 35677056
[TBL] [Abstract][Full Text] [Related]
5. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
[TBL] [Abstract][Full Text] [Related]
6. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
Cassady K; Martin PJ; Zeng D
Front Immunol; 2018; 9():3061. PubMed ID: 30622541
[TBL] [Abstract][Full Text] [Related]
7. Having it both ways: how STAT3 deficiency blocks graft-versus-host disease while preserving graft-versus-leukemia activity.
Brandstadter JD; Outen R; Maillard I
J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526083
[TBL] [Abstract][Full Text] [Related]
8. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
9. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.
Asakura S; Hashimoto D; Takashima S; Sugiyama H; Maeda Y; Akashi K; Tanimoto M; Teshima T
J Clin Invest; 2010 Jul; 120(7):2370-8. PubMed ID: 20530875
[TBL] [Abstract][Full Text] [Related]
10. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
[TBL] [Abstract][Full Text] [Related]
12. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of T-cell-suppressive PD-L1
Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
15. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 serves as a double agent in separating GVL from GVHD.
Brennan TV; Yang Y
J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
Sykes M; Harty MW; Szot GL; Pearson DA
Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
[TBL] [Abstract][Full Text] [Related]
19. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
20. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
